July 2026 verification
Scope of the technical checks
The verification concerned one version of SpoonConsole deployed to a production environment in July 2026. Technical checks were performed with an authenticated account in an access-controlled environment.
Deployment and page delivery
Deployment was limited to the clinician and research-operations console, and the ten principal pages were confirmed to respond.
Authentication boundary
Unauthenticated requests to protected functions were confirmed to be rejected. This was a technical check of the authentication boundary, not acceptance of the full clinical operation.
In-visit review flow
With an authenticated account that included clinician permissions, switching between multiple review contexts within the same institution kept the selected context and displayed information consistent.
Information not retained
The public-facing verification evidence did not retain authentication tokens, user IDs, names, electronic health-record codes, or medical-data content.
This was a limited technical verification of the version deployed in July 2026. It was not independent product certification, user acceptance testing, or production verification of every subsequent change.
Evidence boundaries
Public registration and technical evidence establish different facts.
The jRCT record and the software evidence concern different objects of verification.
jRCT study record
jRCT1040260010 publishes the plan and registered outcomes for a multicentre feasibility study of 12-week use of Spoon DTx in addition to standard outpatient care. The registry does not technically verify implementation, deployment, or operation of the software.
July 2026 technical evidence
ViveSpoon's release evidence records deployment of one SpoonConsole version to a production environment and an authenticated technical smoke test. It is not an independent third-party audit.
External company and people sources
Public records from Japan's National Tax Agency, Kanazawa University, jRCT, AMED, NEDO, and FASTAR separately corroborate company, researcher, registered-study, or selection facts. They are not used to infer product performance, clinical efficacy, ownership, or commercial availability.
Current stage
Current development stage
- Clinician and research-operations MVP
- Implemented
- Technical smoke test of the July 2026 deployed version
- Completed
- Multicentre feasibility study
- Study plan registered in jRCT
- Participant enrolment, intervention start, or clinical use
- Not claimed as started by this page
- Quality, regulatory, security, and healthcare-delivery foundations
- In preparation
- Public or commercial availability
- Not available
We do not claim that the version checked in July 2026 contains every current change or that all later changes have completed production verification.
Intended setting
Intended setting and commercial development
Future use is intended to sit within the clinician–patient relationship and the procedures established by the relevant healthcare or research institution.
Healthcare institutions are the intended future adopting organisations. ViveSpoon does not currently sell the software directly to patients or make it available to the general public. The contracting party, payer, pricing, reimbursement treatment, and timing of revenue generation have not been fixed.
- 01Research software MVPImplemented. Limited technical verification completed for the July 2026 deployed version.
- 02Feasibility evaluationStudy plan registered in jRCT. Registration does not establish results or operations already under way.
- 03Further clinical, quality, and regulatory evaluationAdditional evaluation and delivery foundations are in preparation.
- 04Future healthcare implementationTo be considered only after the necessary evaluation and procedures. Not currently available.
Confidential interfaces
Why the interfaces are not publicly disclosed
Patient-facing and clinician-facing screens, treatment content, navigation, clinical-study procedures, and implementation logic are not shown on this website.
They include confidential product-development information, interface design, and clinical-research implementation information. Any broader disclosure will be considered after intellectual-property, jurisdiction-specific regulatory, research-ethics, and research-lead review. This is ViveSpoon's disclosure policy; it is not a claim that publication of all interfaces is categorically prohibited by law.
If an authorised reviewer provides a secure confidential-review process, ViveSpoon can consider whether additional technical evidence may be provided after confirming the requested scope, submission method, and confidentiality conditions.
Safety boundary
Safety boundary of this page
This page does not provide medical advice, diagnosis, or treatment, and it does not recruit participants for research.
The software is not a substitute for continuous clinician monitoring or emergency response. Anyone needing urgent medical assistance should not use this website for help and should contact local emergency services or a healthcare provider.